Genematrix

본문 바로가기

ENG
ENG
Home  >  Genematrix  >  History
HISTORY

HISTORY

Genematrix (2000 ~ Present)

  • 2020
    • Export license for COVID-19 diagnostic kit 'NeoPlex™ FluCOVID-19 Detection Kit'
    • Concluded contract with UNICEF to supply COVID-19 diagnostic kit
    • Patent application for new technology based on T-cell immunotherapy
    • COVID-19 diagnostic kit 'NeoPlex™ COVID-19 Detection Kit’ approved by US FDA for emergency use
    • Respiratory diagnostic product 'NeoPlex™ RV-panal A Detection Kit’ approved by the Ministry of Food and Drug Safety
    • Obtained permission to export COVID-19 diagnostic kit 'NeoPlex™ COVID-19 Detection Kit’
    • Digestive organs diagnosis product 'NeoPlex™ GI-virus 6 Detection Kit’ approved by the Ministry of Food and Drug Safety
  • 2019
    • Respiratory diagnostic product 'NeoPlex™ RV-panel A Detection Kit’ granted European CE certification
    • Obtained patent for the composition of viral coat protein and zika protein production
    • Merged with Genematrix Bio Co., Ltd.
    • Respiratory disease causative bacteria diagnosis product 'NeoPlex™ RB-8 Detection Kit’ approved by the Ministry of Food and Drug Safety
    • C-TAG technology patent registration (10-1961642)
  • 2018
    • £4 million investment in UK vaccine development company (Vaccitech Limited)
    • Sexually transmitted disease diagnosis product 'Neoplex STI-12’ approved by the Ministry of Food and Drug Safety
  • 2017
    • Granted CE certification for sexually transmitted disease diagnosis product 'Neoplex STI-7’
    • CE certification for molecular diagnosis software 'Neoplex Viewer’
    • Selected as an excellent brain competency company (2017 K-Brainpower) (Ministry of Commerce, Industry and Energy)
    • Sexually transmitted pathogen multi-diagnosis product (Neoplex STI-7) approved by the Ministry of Food and Drug Safety
    • Registered patent for 'Method for Sequencing the Target Site of a Gene' (10-1738596)
    • New product for cervical cancer diagnosis (OmniPlex-HPV) approved by the Ministry of Food and Drug Safety
  • 2016
    • Concluded contract for Zika Virus Vaccine Candidate Material Development and Efficacy Evaluation System Construction Service Project.
    • Registered European patent for 'Amplification Method for Genes with Various Mutations’
  • 2014
    • HBV Entekabier Entrance New Medical Technology Registered
    • Patent for natural-derived anti-cancer drugs
    • Kim Soo-ok took office as CEO
  • 2013
    • KFDA item authorization for eight in vitro medical devices
    • Papillotyper, CE certified
    • Development of HIV-tailored Treatment Diagnostics
  • 2012
    • Enter organic certification business
    • Headquarters relocation (Korea Bio Park)
  • 2011
    • Acquisition of HBI, a venture company specializing in diagnostic drugs
    • Development of hepatotyper for early diagnosis of liver cancer
  • 2010
    • Cross license agreement with Riversense, USA
    • Received the Presidential commendation for venture company
  • 2009
    • Earned the RFMP certification (US 7,541,148)
    • Supervised International Joint Research and Development Project by the Ministry of Knowledge Economy
    • Listed on KOSDAQ
  • 2008
    • Publication in Nature Protocols
    • Selected as a national new growth-engine industry
  • 2007
    • Confirmed for Innovation Business (Inno-Biz)
    • Received the GSK Hepatitis Academic Award (Korean Association for the Study of the Liver)
    • Received the Patent Grand Prize, King Sejong Award (Korean Intellectual Property Office)
  • 2006
    • Awarded the Grand Prize at the Asian Pacific Association for the Study of the Liver
    • Publication in Gastroenterology
    • Publication in Gut
    • Publication in Hepatology
  • 2005
    • Patent registered for RFMP technology in Korea (No. 477766)
    • Received the GSK Hepatitis Academic Award (Korean Association for the Study of the Liver)
    • Selected as one of the Top 100 Successful Industrial Technology Development Projects
  • 2003
    • RFMP Technology Licensing Out (Clinical Genotyping Technology)
    • Joint core technology development projects of the Ministry of Commerce Industry and Energy (Virus molecular diagnostics)
  • 2002
    • Health and medical development projects of the Ministry of Health and Welfare
    • Common food technology development business of the Ministry of Commerce Industry and Energy
    • Development of drug resistant viral genetic analysis for hepatitis therapy
  • 2001
    • Establishment of an affiliated research institute (within the Institute of Cancer Research, Seoul National University College of Medicine)
    • Strategic alliance with Variagenics, USA (Development of Genetic Marker in Pathway of Drug Action)
    • Certified venture business (New technology)
    • Certified as the venture business (New technology)
  • 2000
    • Establishment of Genematrix, Inc.

회원로그인

회원가입

Address.

  • Headquarters / R&D Center : 700 (Sampyeong-dong 694-1) Korea Bio Park B-dong 7, 8, 463-400, Daewang Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do
  • Anyang Warehouse : 140 (Gwanyang-dong 823) Dongil Techno Town 7th Bulmal, Dongan-gu, Anyang-si, Gyeonggi-do

Company.

  • Tel : +82-31-628-2000
  • E-mail: sales@genematrix.net

Product.

  • Biochemical Diagnostics : +82-31-628-2124
  • Molecular Diagnostics : +82-31-628-2045
  • E-mail: sales@genematrix.net

Fax.

  • +82-31-628-2002
Copyright 2020 © Genematrix Inc., All rights reserved.